secwatch.observer — SEC 8-K summary
======================================

Issuer:     ONCOLYTICS BIOTECH INC (ONCY)
CIK:        0001129928
Form:       8-K
Filed at:   2026-04-01T23:59:59+00:00
Accession:  0001104659-26-038272
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 3.03, 5.03, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncolytics Biotech completes redomestication to Nevada; adopts new equity plan and governance documents
--------------------------------------------------------------------------------

- Redomestication from Canada to Nevada completed; common stock continues trading on Nasdaq under ONCY.
- New CUSIP 68237V 103 and ISIN US68237V1035 effective April 1, 2026.
- Board adopted 2026 Incentive Award Plan with 6.5M initial shares plus annual evergreen increase up to 6% of outstanding.
- New indemnification agreements executed with all executive officers and directors.
- Risk factor update warns of reduced stockholder rights under Nevada law, including exclusive forum provisions and no cumulative voting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1129928/000110465926038272/0001104659-26-038272-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1129928/000110465926038272/tm2610715d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-038272

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer